Articles

Navigating the Analytical and Regulatory Frontiers of Cell and Gene Therapy 

Dr. Jared Auclair breaks down the critical QC bottlenecks, MAM implementation challenges, and hybrid talent gaps shaping the future of advanced therapeutics. 
Updated
Written byShiama Thiageswaran
InterviewingJared Auclair
Artistic representation of cell and gene therapies concept

iStock

Register for free to listen to this article
Listen with Speechify
0:00
7:00

For decades, the biopharmaceutical industry has relied on a foundational playbook optimized for monoclonal antibodies (mAbs). These large-batch, identical blockbusters allowed workflows to be meticulously perfected from research through to commercial release. However, the rapid ascent of cell and gene therapies (CGTs)—specifically autologous cell therapies—is rendering traditional biomanufacturing and quality-control paradigms obsolete.

To explore how the analytical community must adapt to this new frontier of medicine, we spoke with Dr. Jared Auclair, an analytical biochemist, mass spectrometrists by training, and an expert in regulatory science at Northeastern University’s Center of Bioinnovation . Dr. Auclair shared insights into the primary bottlenecks facing bench scientists, the crucial role of analytical chemistry in global regulatory convergence, and why the maturity of CGT quality frameworks requires a complete rethink of the industry's approach.

The Maturity Metaphor

To contextualize the current state of quality control in advanced therapeutics, Dr. Auclair draws a sharp contrast between long-established modalities and emerging platforms.

Working in analytical science?

Register for a FREE Separation Science account to subscribe to the Separation Science Newsletter.

Subscribe for free

"If we look at three distinct product classes—small molecules, mAbs, and CGTs—the maturity of their quality paradigms is vastly different," explains Auclair. "Consider the analytical landscape through the lens of infrastructure: small molecule quality paradigms represent a fully realized, furnished house that the industry has occupied for generations. While monoclonal antibodies are relatively comparable and require only minor structural adjustments, cell and gene therapies remain in the skeletal framing stage. This fundamental lack of maturity creates an opening to integrate revolutionary analytical frameworks."

Breaking Traditional Quality Control Paradigms

The defining trait of autologous cell therapies is their biological variability; the patient is the starting material, and the batch size is exactly one. This fundamental characteristic shatters centralized, high-throughput manufacturing frameworks and necessitates distributed manufacturing models—producing therapies at or near the hospital site.

"While the vast majority of cell therapies on the market today are autologous, there is an active industry push toward standardizing allogeneic, or 'off-the-shelf,' treatments in the future," asserts Auclair. “Hopefully, we will see more allogeneic therapies down the line that allow for larger-batch manufacturing. But right now, we are dealing primarily with autologous treatments, and that lends itself to the necessity for distributed manufacturing."

This decentralized approach introduces unique hurdles for good manufacturing practices (GMP) and real-time release.

"Distributed manufacturing causes all kinds of challenges in the context of what GMP looks like and how we ensure quality, efficacy, and safety," advises Auclair. "However, it also presents an opportunity to rethink the quality paradigm entirely. We can pull samples online, analyze them in real time, and lean heavily into the strengths of process analytical technology (PAT), artificial intelligence (AI), and machine learning (ML)."

Resolving the Sample Volume and Time Crunch

For live cellular products, time is the ultimate constraint. Standard compendial QC assays can take weeks to complete—a timeline that often exceeds the viability and shelf life of the living cells required by a severely ill patient. Furthermore, while a 2,000-liter monoclonal antibody bioreactor run affords a laboratory ample sample volume for testing, cell therapies yield microscopic amounts of material.

"In the cell and gene therapy space, you don't only have a time crunch issue; you have a sample volume issue," stresses Auclair. "You only have a small volume of sample to execute as many quality tests as humanly possible. This is driving a massive industry push toward rapid, near-time characterization."

To accelerate this timeline, the industry is increasingly moving from offline sampling to inline analytical methods, such as probe-based Raman spectroscopy, which measure directly inside the active bioreactor bag.

"The less we physically manipulate these products, the better," Auclair explains. "With probe-based Raman spectroscopy, you can literally insert the probe directly into the culture bag to get real-time, inline, as opposed to online, characterization. Minimizing product manipulation is particularly critical in this space, as many of these recipients are severely ill and non-responsive to previous therapies, and have virtually no biological margin for error."

This push for speed has also dramatically redefined chromatographic runtimes.

"Back in the day, we used to run five-hour gradients on liquid chromatography systems to achieve high-resolution separations," says Auclair. "Now, we are running gradients on the order of minutes. While we can never prioritize speed at the expense of sample size or data quality, the technical progression toward rapid, near-time characterization is outstanding."

Mass Spectrometry Innovations and Vector Bottlenecks

Characterizing viral vectors, such as adeno-associated viruses (AAVs) and lentiviruses, remains one of the most complex tasks in gene therapy, particularly when determining empty-to-full

capsid ratios. Interestingly, Auclair points out that the core limitation is no longer the physical hardware.

"The instrumentation itself is actually quite good; we can measure large, complex molecules accurately. The primary bottlenecks are on the front end, with sample preparation, and on the back end, with bioinformatics. Historically, data analysis tools have struggled to keep pace with hardware developments, and software packages are frequently unoptimized for the extreme structural complexity of these vectors."

For veteran mass spectrometrist readers, Auclair compares the current stage of vector analysis to an earlier era of biopharmaceutical testing.

"To me, this stage of AAV and viral vector characterization feels similar to when we first started analyzing glycans, or sugars, on proteins," he recalls. "In the early days, the characterization was such an intimidating headache. Today, glycoprotein profiling is entirely streamlined. That is exactly where we are with AAV characterization right now—it is notoriously difficult, but the field will mature and standardize in the same way."

Beyond characterization hurdles, Auclair observes that the choice of delivery platform is a subject of active industry debate.

"I often find myself advocating for developers to look beyond traditional viral delivery methods. I'm not a huge fan of AAVs due to persistent toxicity concerns and other clinical complications. I believe lipid nanoparticles (LNPs) represent a much safer, more stable delivery system for these advanced therapies, and our analytical workflows must evolve to fully support both modalities."

Until a single "one and done" analytical system matures, Auclair recommends a robust orthogonal characterization strategy—using mass spectrometry alongside bioluminescence, for instance—as a necessity. He also highlights the vast potential of charge-detection mass spectrometry (CDMS) for resolving megadalton-sized molecules. While high costs and limited familiarity have historically slowed uptake, the commercialization of CDMS as accessible add-on systems for existing mass spectrometers means it will likely become an essential component of the CGT quality paradigm over time.

Bridging the MAM Ruggedness Gap in cGMP Environments

The multi-attribute method (MAM) via LC-MS represents an analytical "holy grail" for consolidating workflows into a single, cost-effective run. However, transferring complex, resource-intensive mass spectrometry data from specialized discovery labs to a rugged, compliant cGMP routine QC environment introduces serious data integrity and operational friction.

"MAM is incredibly appealing because you can check multiple quality boxes via sequence coverage, post-translational modifications (PTMs), and new peak detection in a single, cheaper

experiment. Moving it into the QC space is uniquely challenging because it shifts the workflow from a specialized mass spectrometrist to a technician,” observes Auclair.

"In my experience training personnel, the plumbing and sheer visual complexity of a high-performance liquid chromatography (HPLC) system—with fluid lines and solvent bottles everywhere—is often more intimidating to a new user than the mass spectrometer itself, which has essentially become a streamlined box.”

To bridge this gap, modern MAM workflows prioritize dedicated software tools designed for workflow use. This ensures data integrity and reproducibility are maintained natively, outputting clean results alongside robust audit trails required for FDA inspections across all product classes."

The Rise of the Hybrid Scientist

As vendor instrumentation becomes more automated, increasingly sophisticated liquid samplers handle complex front-end prep, and downstream analytics require deep data interpretation, the profile of a successful laboratory bench scientist is evolving. Traditional siloes between computer science and wet chemistry are no longer tenable.

"The single biggest skill gap we see right now is the lack of a 'hybrid' person who can bridge analytical biochemistry, live biology, and data analysis or bioinformatics," emphasizes Auclair. "We have scientists who excel at structural biochemistry and computer professionals who understand hard data analysis, but finding talent that commands both is incredibly rare."

"Another massive gap exists in training personnel for automation, which is dominating sample preparation and manufacturing. The academic world is still frequently teaching students how to manually pipette rather than training them to interact with, program, and validate the robots that perform the pipetting. Formal, cross-functional training in data science and automated architecture is currently lacking at the scale the biopharmaceutical industry demands."

Critical Need for Global Regulatory Convergence

The rapid global explosion of novel cell and gene therapies has outpaced regulatory harmonization. Because advanced therapies are often produced in micro-batches for small, highly specific patient populations, navigating highly discrepant analytical characterization guidelines across different sovereign borders can become a prohibitive commercial barrier.

Auclair distinguishes between two frequently confused terms in regulatory science: harmonization and convergence. "Regulatory harmonization implies making laws and regulations across distinct countries exactly identical, which is practically impossible due to localized legal structures. Therefore, we must champion regulatory convergence—aligning international agencies to operate under similar, standardized guidelines."

Despite this urgent need, the formal guideline infrastructure remains heavily underdeveloped. Dr. Auclair points out that the International Council for Harmonization (ICH)—the leading body for aligning global pharma standards—is only beginning to address the space.

"The ICH is excellent at developing unified guidelines, but currently, they only have one specific guideline dedicated to cell and gene therapies, while others are still in the early stages of development. It is an incredibly nascent space, meaning we are trying to establish guidelines retrospectively, long after the initial product explosion has occurred."

Auclair’s perspective is grounded in real-world international policy training.

"I do a lot of work teaching regulators about cell and gene therapies in Africa, and the very first question they ask is always about price and access," Auclair shares. "This is where convergence becomes so vital. If a developer has to compile highly different, localized regulatory dossiers for every single country, the overhead is astronomical. By driving toward global convergence, we can dramatically lower development and manufacturing costs. Lowering the cost of these therapies globally directly impacts their pricing and accessibility back home in the United States and Canada as well."

Future Desired Innovations: What the Labs Want from Vendors

When looking toward instrument design in the coming years, Auclair puts forth a clear wishlist for instrument and single-use hardware vendors:

  • Continued miniaturization: Mass spectrometers that once occupied entire rooms have shrunk to wall- or benchtop footprints, but further miniaturization is needed to place tools directly in localized point-of-care manufacturing sites.
  • Streamlining LC systems: Redesigning and simplifying the fluidics and plumbing layout of HPLCs to minimize complexity and make tools significantly more user-friendly for non-expert operators.
  • Inline analytical integration: Further advancement of probe-based methods, such as Raman spectroscopy, that can be integrated directly into live culture bags to track cellular shifts without physical sample manipulation.
  • Green analytical chemistry innovations: A substantial transformation in the sustainability of single-use disposable systems and fluidic architectures.

"We utilize single-use systems extensively in cell and gene therapy manufacturing to ensure sterility and switch quickly between patient lots," concludes Dr. Auclair. "I want to see major vendor innovation aimed at making these disposable architectures more environmentally friendly and 'green'. By leveraging automation and optimizing fluid paths, we can use less water and fewer harsh solvents, which will simultaneously lower overhead costs and minimize the environmental footprint of producing tomorrow's cures."

Responses have been edited for length and clarity.

Add Separation Science as a preferred source on Google

Add Separation Science as a preferred Google source to see more of our trusted coverage

Meet the Author(s):

Interviewing

  • Jared Auclair

    Jared Auclair serves as the Dean of the College of Professional Studies at Northeastern University. Appointed in December 2024, Jared leads all academic and administrative functions of the college.

    With more than a decade of experience at Northeastern, starting first as a post-doc and most recently, Vice Provost Research Economic Development and Director of Bioinnovation, Jared is a champion of innovation and collaboration and deeply values the promise that the College of Professional Studies brings to students as one of Northeastern’s most diverse and dynamic colleges committed to meet students where they are.

    Prior to his role as Vice Provost Research Economic Development, Jared served as the Associate Dean of Professional Programs and Graduate Affairs in the College of Science, and still holds a faculty appointment in the Department of Chemistry and Chemical Biology. His past experience with the College of Professional Studies includes leadership on a variety of economic and workforce development and research programs, including PlusOne, a dynamic program that gives students the opportunity to accelerate their education by earning both a bachelor’s and master’s degree in five years.

    With an extensive leadership background, Jared’s passion for progress drives essential strategic initiatives for the College of Professional Studies. His focus on strengthening the connections between education, research, and community, along with fostering a global mindset is core to the College of Professional Studies’ commitment to delivering a world-class experiential education tailored to students’ needs.

    Prior to joining Northeastern, Jared held a variety of research and consulting roles for leading biopharmaceutical firms. He holds a bachelor’s degree in biotechnology from Worcester Polytechnic Institute and a PhD in Biomedical Science from the University of Massachusetts Medical.

    View Full Profile

Here are some related topics that may interest you:

Loading Next Article...
Loading Next Article...